Skip to main navigation
Close
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Supply Chain Blueprint
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Menu
New White Paper
- Read AAM Report on Drug Shortages
Learn More
Close
Breadcrumb
Association for Accessible Medicines
Resources
Press Releases
Press Releases
Share
Press Release
Dec 20, 2022
| Susan Reilly
AAM Statement on the Consolidated Appropriations Act of 2023
Press Release
Dec 13, 2022
| Susan Reilly
AAM Statement on CMS's Proposed Rule Requiring Generic Drugs to be Covered on Generic Tiers
Press Release
Nov 14, 2022
| Susan Reilly
Raising Awareness for Biosimilars for Stakeholders Around the World
Press Release
Oct 14, 2022
| Susan Reilly
AAM Statement on President Biden's Executive Order on Lowering Prescription Drug Costs
Press Release
Oct 3, 2022
| Susan Reilly
AAM Statement on the Centers for Medicare & Medicaid Services’ Implementation of Medicare Part B Payment Changes for Biosimilars
Press Release
Sep 21, 2022
| Susan Reilly
Generic and Biosimilar Drugs Generate A Record $373 Billion For America’s Patients and Healthcare System in 2021
Press Release
Sep 15, 2022
| Susan Reilly
AAM Statement: New Study Shows Formulary Abuses Force Patients to Pay More for Generic Drugs Even as the Prices of Those Drugs Go Down
Press Release
Aug 7, 2022
| Allen Goldberg
AAM Statement on Senate Passage of Inflation Reduction Act
Press Release
Jul 28, 2022
| Allen Goldberg
Association for Accessible Medicines (AAM) Elevates David Gaugh to Executive Vice President for Sciences & Regulatory Affairs
Press Release
Jul 6, 2022
| Allen Goldberg
AAM Statement on BBB 2.0
Press Release
Jun 6, 2022
| Allen Goldberg
Giuseppe Randazzo Joins AAM as Vice President, Sciences and Regulatory Affairs
Press Release
May 23, 2022
| Allen Goldberg
AAM Statement in Response to Federal Trade Commission Request for Information on PBM Business Practices
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
GRx+Biosims 2022
Access! 2022
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Supply Chain Blueprint
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action